BioXcel Therapeutics, Inc. (BTAI) financial statements (2022 and earlier)

Company profile

Business Address 555 LONG WHARF DRIVE
NEW HAVEN, CT 06511
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments232,968213,11932,42642,565
Cash and cash equivalents232,968213,11932,42642,565
Receivables   115
Other current assets956   
Other undisclosed current assets2,8883,9461,681491
Total current assets:236,812217,06534,10743,171
Noncurrent Assets
Operating lease, right-of-use asset1,2471,5111,193
Property, plant and equipment1,2941,2731,041327
Other noncurrent assets86875151
Total noncurrent assets:2,6272,8712,285378
TOTAL ASSETS:239,439219,93636,39243,549
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities16,17011,4488,0734,660
Accounts payable4,6783,9794,9531,604
Accrued liabilities11,4927,4693,1203,056
Due to related parties204   
Other liabilities293237331 
Other undisclosed current liabilities 15764 
Total current liabilities:16,66711,8428,4684,660
Noncurrent Liabilities
Long-term debt and lease obligation1,1051,3981,029 
Operating lease, liability1,1051,3981,029
Other undisclosed noncurrent liabilities(1,105)(1,398)  
Total noncurrent liabilities:1,1051,3981,029 
Total liabilities:17,77213,2409,4974,660
Stockholders' equity
Stockholders' equity attributable to parent221,667206,69626,89538,889
Common stock28241816
Additional paid in capital467,427345,52983,56562,593
Accumulated deficit(245,788)(138,857)(56,688)(23,720)
Total stockholders' equity:221,667206,69626,89538,889
TOTAL LIABILITIES AND EQUITY:239,439219,93636,39243,549

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues
(Net Investment Income)
 155  
Gross profit: 155  
Operating expenses(106,935)(82,297)(33,601)(19,962)
Other undisclosed operating loss (155)  
Operating loss:(106,935)(82,297)(33,601)(19,962)
Nonoperating income
(Investment Income, Nonoperating)
44   
Interest and debt expense(40)(27)  
Loss before gain (loss) on sale of properties:(106,931)(82,324)(33,601)(19,962)
Other undisclosed net income  633692
Net loss:(106,931)(82,324)(32,968)(19,270)
Other undisclosed net income attributable to parent 155  
Net loss available to common stockholders, diluted:(106,931)(82,169)(32,968)(19,270)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(106,931)(82,324)(32,968)(19,270)
Comprehensive loss, net of tax, attributable to parent:(106,931)(82,324)(32,968)(19,270)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: